This technology uses peptides secreted by engineered bacteria to reduce virulence of Fusobacterium nucleatum.

This technology is a comprehensive compound design and preclinical testing platform that can be used to develop multifunctional drugs for Alzheimer’s disease, and has already led to the development of several promising lead compounds.

This technology is a tool to identify compounds that block the activity of TIA1, an RNA-binding protein that regulates stress granule formation and the generation of pathological forms of tau protein, and is implicated in a range of neurodegenerative diseases.

This technology, FixR, is a modified peptide and delivery system aimed at reducing pathogenic late sodium currents, which are implicated in cardiac and neurological diseases, including cardiac arrhythmia.

This technology is a series of compounds that modulate ferroptosis for the treatment of excitotoxic and degenerative diseases.

This technology is a small molecule protein therapeutic for systolic heart failure, which improves contractility without an unwanted rise in a patient’s heart rate.

This technology targets CREB3L2 for the treatment of neurodegenerative diseases, including Parkinson’s and Alzheimer’s diseases.

This technology is a set of small molecule agonists of the Sigma non-opioid receptor for the treatment of Timothy Syndrome.

This technology is a targeted anti-tumor agent designed to treat adenoid cystic carcinoma (ACC) by utilizing retinoid receptor modulation to promote cancer cell differentiation and selective cell death.

This technology is a method of reprogramming cellular metabolism to treat neurodegenerative disorders by downregulating catabolism and upregulating anabolism in cells.

This technology is an immunosuppressant that suppresses T cell proliferation and can be used to treat organ transplant rejection and autoimmune or inflammatory conditions.

This technology describes the mechanism of action and use of compound FIN56, a specific inducer of ferroptosis.

This technology is a method for inducing non-apoptotic death of cancer cells in a regulated manner for more efficacious radiation therapy.

This technology uses S-methyl-L-Thiocitrulline, a neuronal nitric oxide synthase inhibitor, and its derivatives as a pharmacological treatment for the prevention and treatment of myopia.

This technology is a library of compounds designed to target key pathways of eye development that can be used to treat myopia.